TGF-β uses the E3-ligase TRAF6 to turn on the kinase TAK1 to kill prostate cancer cells

Future Oncology

Volumn 5, Issue 1, 2009, Pages 1-3

  Thakur, Noopur ^a   Sorrentino, Alessandro ^a,b   Heldin, Carl Henrik ^b   Landström, Maréne ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE LKB1; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE;

APOPTOSIS; BONE METASTASIS; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; EDITORIAL; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; UBIQUITINATION; ANIMAL; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MALE; MAP KINASE KINASE KINASES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6; TRANSFORMING GROWTH FACTOR BETA;

EID: 65349096856     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.5.1.1     Document Type: Editorial

References (27)

1. Massagué J: TGFβ in cancer. Cell 134(2), 215-230 (2008).
2. Heldin CH, Miyazono K, ten Dijke P: TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 390(6659), 465-471 (1997).
3. Sorrentino A, Thakur N, Grimsby S et al.: The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol. 10(10), 1199-1207 (2008).
4. Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 15 (6), 740-746 (2003).
5. Nawshad A, Lagamba D, Polad A, Hay ED: Transforming growth factor-β signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs 179(1-2), 11-23 (2005).
6. Moustakas A, Heldin CH: Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 98(10), 1512-1520 (2007).
7. Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7(2), 131-142 (2006).
8. Yamaguchi K, Shirakabe K, Shibuya H et al.: Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 270(5244), 2008-2011 (1995).
9. Adhikari A, Xu M, Chen ZJ: Ubiquitin-mediated activation-of TAK1 and IKK. Oncogene 26(22), 3214-3226 (2007).
10. Momcilovic M, Hong SP, Carlson M: Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem. 281(35), 25336-25343 (2006).
11. Xie M, Zhang D, Dyck JR et al.: A pivotal role for endogenous TGF-β-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc. Natl Acad. Sci. USA 103(46), 17378-17383 (2006).
12. Carling D, Sanders MJ, Woods A: The regulation of AMP-activated protein kinase by upstream kinases. Int. J. Obes. Lond. 32(Suppl. 4), S55-S59 (2008).
13. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ: TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412(6844), 346-351 (2001).
14. Kanayama A, Seth RB, Sun L et al.: TAB2 and TAB3 activate the NF-κB pathway through binding to polyubiquitin chains. Mol. Cell 15(4), 535-548 (2004).
15. Deng L, Wang C, Spencer E et al.: Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103(2), 351-361 (2000).
16. Baselga J, Rothenberg ML, Tabernero J et al.: TGF-β signalling-related markers in cancer patients with bone metastasis. Biomarkers 13(2), 217-236 (2008).
17. Berry PA, Maitland NJ, Collins AT: Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells. Mol. Cell. Endocrinol. 288(1-2), 30-37 (2008).
18. Birnie R, Bryce SD, Roome C et al.: Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol. 9(5), R83 (2008).
19. Zhu ML, Kyprianou N: Androgen receptor and growth factor signaling partnerships in prostate cancer cells. Endocr. Relat. Cancer 15(4), 841-849 (2008).
20. Karin M: Nuclear factor-κB in cancer development and progression Nature 441(7092), 431-436 (2006).
21. Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425(6958), 577-584 (2003).
22. Moustakas A, Heldin CH: Non-Smad TGF-β signals. J. Cell Sci. 118(Pt 16), 3573-3584 (2005).
23. Bogdahn U, Oliushine VE, Parfenov VE et al.: Results of G004, a Phase IIb study in recurrent glioblastoma patients with the TGF-β2 targeted compound AP 12009. J. Clin. Oncol., 2006 ASCO Annual Meeting Proceedings 24(18S) (2006) (Abstract 1553).
24. Li MO, Flavell RA: TGF-β: a master of all T cell trades. Cell 134(3), 392-404 (2008).
25. Taylor AW. Review of the activation of TGF-β in immunity. J. Leukoc. Biol. 85(1), 29-33 (2008).
26. Xiao H, Zhang YY. Understanding the role of transforming growth factor-β signalling in the heart: overview of studies using genetic mouse models. Clin. Exp. Pharmacol. Physiol. 35(3), 335-341 (2008).
27. Liu W, Chang BL, Cramer S et al.: Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin. Cancer Res. 13(17), 5028-5033 (2007).